Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | RAB9A | P51151 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | MAOB | P27338 | 7/20 | 0.60 |
| ▸ | MAOA | P21397 | 6/20 | 0.60 |
| ▸ | PRKCI | P41743 | 1/20 | 0.58 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30026512 | 1.00 | NPC1 (0.63) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL5490235 | 0.86 | ESR1 (0.60) | NPC1RAB9AMAPTMAOA | |
| SCHEMBL29978546 | 0.86 | ESR1 (0.60) | NPC1RAB9AMAPTMAOA | |
| SCHEMBL22803696 | 0.86 | NPC1 (0.67) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL4347943 | 0.84 | NPC1 (0.69) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL31668688 | 0.84 | MAOA (0.66) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL24196796 | 0.84 | NPC1 (0.54) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL29035928 | 0.83 | NPC1 (0.52) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL5177372 | 0.83 | MAOB (0.83) | NPC1RAB9AMAPTMAOBMAOA | |
| SCHEMBL721964 | 0.83 | MAOB (0.65) | NPC1RAB9AMAPTMAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377447-B2 | Targeted therapeutics | MADRIGAL PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| WO-2020257621-A1 | METHODS OF TREATING CANCER | IFM DUE, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| US-20200239472-A1 | TARGETED THERAPEUTICS | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2020-07-30 | — | — | US | disclosed |
| EP-3305763-B1 | DEUTERATED OR ISOTOPICALLY LABELED UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FPRL-1 AGONISTS | KYORIN SEIYAKU KK (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2012-05-24 | — | — | US | disclosed |
| EP-2308871-A1 | Substituted indole compounds and their use as 5-HT6 receptor modulators | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-04-13 | — | — | EP | disclosed |
| EP-1660131-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2009-06-24 | — | — | EP | disclosed |
| EP-1648445-B1 | INDOL-5-YL SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE 5-HT-6 AS MODULATORS | ESTEVE LABOR DR (ES) | 2009-06-03 | — | — | EP | disclosed |
| EP-1648468-B1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | ESTEVE LABOR DR (ES) | 2008-09-24 | — | — | EP | disclosed |
| CN-101068809-A | Substituted indole compounds and their use as 5-ht6 receptor modulators | ESTEVE LABOR DR (ES) | 2007-11-07 | — | — | CN | disclosed |
| EP-1648468-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| EP-1648445-A1 | INDOL-5-YL SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE 5-HT-6 AS MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| WO-2006024535-A1 | SUBSTITUTED INDOLE COMPOUNDS AND THEIR USE AS 5-HT6 RECEPTOR MODULATORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-09 | — | — | WO | disclosed |
| EP-1632491-A1 | Substituted indole compounds and their use as 5-HT6 receptor modulators | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-03-08 | — | — | EP | disclosed |
| US-6858577-B1 | Indole peptidomimetics as thrombin receptor antagonists | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2005-02-22 | — | — | US | disclosed |
| WO-2005014000-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005013977-A1 | INDOL-5-YL SULFONAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE 5-HT-6 AS MODULATORS | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014045-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE S.A. (DE) | 2005-02-17 | — | — | WO | disclosed |
| WO-2001000657-A2 | NOVEL INDOLE PEPTIDOMIMETICS AS THROMBIN RECEPTOR ANTAGONISTS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2001-01-04 | — | — | WO | disclosed |
| US-5418237-A | Indole derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239472-A1 | TARGETED THERAPEUTICS | CDC37, HSP90AB1, HSP90B1 | NPC1 692/4885RAB9A 1747/4885MAPT 811/4885 |
| US-11377447-B2 | Targeted therapeutics | CDC37, HSP90AB1, HSP90B1 | NPC1 692/4885RAB9A 1747/4885MAPT 811/4885 |
| US-20120128768-A1 | ACTIVE SUBSTANCE COMBINATION COMPRISING A COMPOUND WITH NPY RECEPTOR AFFINITY AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, NPY5R, NPY2R | NPC1 2956/4885RAB9A 4275/4885MAPT 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.